clinical trial · NCT05336409
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
R/R CD19-Positive B-Cell MalignanciesIndolent Non-Hodgkin LymphomaAggressive Non-Hodgkin LymphomaCNTY-101IL-2Lymphodepleting Chemotherapy
brief summary
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.
started
Jan 24, 2023
primary completion
Jul 1, 2025
completion
Jul 1, 2025
last updated
Dec 18, 2025
official title
The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol